Physician profile
Richard Snouffer
NPI 1821006628
$3,230.44
in general payments reported to CMS, 2019-2025
33 companies · $820 in 2025
The $820 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.11 · 2020: $124 · 2021: $169 · 2022: $290 · 2023: $949 · 2024: $843 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,611.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $750.20 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Indivior INC. | $295.43 | 2019-2025 | Sublocade |
| Novo Nordisk INC | $252.09 | 2022-2025 | Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $241.98 | 2023-2025 | Caplyta |
| Braeburn INC. | $181.70 | 2023-2025 | Brixadi |
| Otsuka America Pharmaceutical, INC. | $158.99 | 2023-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $145.09 | 2023 | Qelbree |
| Lilly USA, LLC | $120.09 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $118.02 | 2023-2025 | Auvelity |
| Dexcom, INC. | $109.36 | 2023 | Dexcom G7 Gss (161) |
| Lundbeck LLC | $98.60 | 2022-2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.78 | 2022-2025 | Relistor |
| Tolmar, INC. | $78.90 | 2023-2024 | |
| Antares Pharma, INC. | $56.95 | 2024-2025 | Xyosted |
| Biohaven Pharmaceuticals, INC. | $56.63 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $52.71 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.65 | 2022-2024 | Trintellix |
| Acella Pharmaceuticals, LLC | $48.68 | 2024-2025 | NP Thyroid 60 |
| Amarin Pharma, INC. | $46.40 | 2020 | |
| Vanda Pharmaceuticals INC. | $30.90 | 2025 | Fanapt |
| Allergan, INC. | $27.99 | 2020 | |
| Corium, LLC | $23.60 | 2023 | Azstarys |
| Astellas Pharma US INC | $23.30 | 2024 | Veozah |
| Noven Therapeutics, LLC | $21.47 | 2024 | Xelstrym |
| Amgen INC. | $19.91 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.88 | 2023 | |
| Orexo US, INC. | $16.51 | 2023 | Zubsolv |
| Kowa Pharmaceuticals America, INC. | $16.15 | 2021 | |
| Exact Sciences Corporation | $15.60 | 2023 | Cologuard Collection Kit |
| Pear Therapeutics (US), INC. | $15.52 | 2022 | |
| Pfizer INC. | $15.33 | 2025 | |
| Gilead Sciences, INC. | $14.59 | 2025 | |
| Idorsia Pharmaceuticals US INC | $13.44 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Snouffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.